GlaxoSmithKline (GSK) Muscular Dystrophy Drug Gets "Breakthrough" Status
6/27/2013 10:18:31 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
GlaxoSmithKline said on Thursday U.S. regulators have given breakthrough therapy status for its investigational compound drisapersen for the potential treatment of patients with duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by